Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Jun 6, 2006

Studies Evaluating Eloxatin®-Based Regimens in Gastrointestinal Cancers Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Jun 3, 2006

Results of a meta-analysis show benefits of TAXOTERE® (docetaxel) regimens in patients with advanced non-small cell lung cancer (NSCLC)

Findings show demonstrated overall survival with less febrile neutropenia for Taxotere(R) versus vinca-alkaloid regimens
Jun 3, 2006

New Phase III data reports on the safety and efficacy of Risedronate for the treatment of male osteoporosis
Jun 1, 2006

Sanofi-aventis General Meeting of Shareholders
May 30, 2006

New ELOXATIN® and TAXOTERE® data in several tumor types to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO)

430 abstracts from studies involving Taxotere(R) or Eloxatin(R) accepted at the meeting's scientific sessions

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.